LITESPARK-024: Randomized phase 1/2 study of belzutifan with or without palbociclib for treatment of advanced renal cell carcinoma (RCC). This is an ASCO Meeting Abstract from the 2023 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results